Sai Life Sciences · forward-looking guidance across the available source record.
Guidance tracker
Management committed to sustaining 28-30% EBITDA margin range (already achieved at 30% for 9M FY26) to balance growth investment with profitability. Operating leverage from employee costs (~450bps) and material margins (~100bps) drove expansion ahead of schedule.
Management expects the CDMO:CRO revenue split to remain broadly within 65:35 to 50:50 range, with variability between years depending on which segment grows faster in any given period.
Hyderabad Unit 8 R&D expansion (200 fume hoods) commissioning Q4 FY26; Process R&D building adding doubling total process R&D capacity by September 2026; Peptide pilot plant by September 2026.
Adding 225KL by June 2026 and another 225KL by Q1 FY27, representing 70% increase in API manufacturing capacity. New site (non-GMP + GMP + peptide) coming online in 18-24 months.
Management reiterated long-term revenue growth guidance of 15-20% CAGR, supported by strong pharma relationships and pipeline.
Aspirational margin range of 28-30% maintained, with FY26 margin at 30% but new capacity inefficiencies expected.
Capex guided at ₹1,100-1,300 crore, with 75% for capacity expansion (including 225kL reactor capacity) and 25% for capabilities/AI.
Due to new capacities coming on stream progressively, second half of FY27 expected to be stronger than first half.